Levodopa
Levodopa (L-DOPA) is an endogenous precursor to dopamine, norepinephrine, and epinephrine; it can also be found in bean plants such as species of Mucuna. L-DOPA increases brain dopamine concentrations and is clinically used to treat symptoms of Parkinson’s disease. Peripheral increases in dopamine cause many side effects, including dyskinesias, hypotension, and nausea.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18939904
| Cas No. |
59-92-7 |
|---|---|
| Purity |
≥98% |
| Formula |
C9H11NO4 |
| Formula Wt. |
197.19 |
| Chemical Name |
3-Hydroxy-L-tyrosine |
| IUPAC Name |
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
| Synonym |
Bendopa; Dopaflex; Dopaidan; Doparl; Dopaston; Eldopatec; L-DOPA; Maipedopa; Parda; Veldopa |
| Melting Point |
276-278°C (dec.) |
| Solubility |
Soluble in water, dil HCl, and formic acid.Practically insoluble in ethanol, benzene, chloroform and ethyl acetate. |
| Appearance |
A white or slightly cream crystalline powder |
Pahwa R, Lyons KE. Treatment of early Parkinsons disease. Curr Opin Neurol. 2014 Jun 19. [Epub ahead of print]. PMID: 24950010.
Pd Med Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinsons disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014 Jun 10. [Epub ahead of print]. PMID: 24928805.
